Advertisement

Infection

pp 1–8 | Cite as

Inappropriate initial antimicrobial therapy for hematological malignancies patients with Gram-negative bloodstream infections

  • Yishu Tang
  • Xinyu Wu
  • Qian Cheng
  • Xin LiEmail author
Original Paper

Abstract

Background

Inappropriate initial antimicrobial therapy (IIAT) may increase the mortality rate of hematological malignancies (HMs) patients with Gram-negative bacteria bloodstream infections (GN-BSI). The aim of this study is to determine whether IIAT affects the prognosis in this patient population and recommend the appropriate antibiotic regimen to minimize IIAT.

Methods

We reviewed a retrospective cohort study of 361 HM patients with neutropenic fever from GN-BSI. The patients’ clinical characteristics and the results of the drug sensitivity test in vitro were analyzed.

Results

IIAT rate was 21.3% in HM patients with neutropenic fever caused by GN-BSI. There was a significant difference in 7-day mortality rate between patients treated with appropriate antibiotics and those with IIAT (7.7% vs 29.9%, p < 0.01). Multivariate analysis confirmed that IIAT was an independent risk factors for early mortality [4.860 (1.541–15.323)]. Drug sensitivity data of GN-bacteria suggested that carbapenems monotherapy or beta-lactamase inhibitors (BLBLI) combined with amikacin as the initial therapy can effectively reduce the IIAT rate. In the stratified antibiogram based on prior antimicrobial exposure, our results showed that BLBLI monotherapy could be initially used as an empirical treatment in patients without prior antimicrobial exposure. In those who had received prior antimicrobial exposure, BLBLI (especially piperacillin–tazobactam) combined with amikacin is recommended.

Conclusions

IIAT was a critical factor contributing to the mortality of HM patients with neutropenic fever from GN-BSI.

Keywords

Inappropriate initial antimicrobial therapy Hematological malignancies Gram-negative bloodstream infections Febrile neutropenia 

Notes

Acknowledgements

We thank all those who helped us in this study, in particular, the Department of Hematology and the Department of Clinical Laboratory for making this study possible. Qing Yang helped us modify the grammar of the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (General Program), no. 81870165 and Fundamental Research Funds for the Central Universities of Central South University, no. 2017zzts837.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest. All authors meet the ICMJE authorship criteria.

Supplementary material

15010_2019_1370_MOESM1_ESM.pdf (182 kb)
Supplementary material 1 (PDF 182 kb)

References

  1. 1.
    Norgaard M, Larsson H, Pedersen G, Schonheyder HC, Sorensen HT. Risk of bacteraemia and mortality in patients with haematological malignancies. Clin Microbiol Infect. 2006;12:217–23.CrossRefPubMedGoogle Scholar
  2. 2.
    Tumbarello M, Spanu T, Caira M, Trecarichi EM, Laurenti L, Montuori E, et al. Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagn Microbiol Infect Dis. 2009;64:320–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Madani TA. Clinical infections and bloodstream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukemia. Infection. 2000;28:367–73.CrossRefPubMedGoogle Scholar
  4. 4.
    Chen CY, Tsay W, Tang JL, Tien HF, Chen YC, Chang SC, et al. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect. 2010;138:1044–51.CrossRefPubMedGoogle Scholar
  5. 5.
    Attman E, Aittoniemi J, Sinisalo M, Vuento R, Lyytikainen O, Karki T, et al. Etiology, clinical course and outcome of healthcare-associated bloodstream infections in patients with hematological malignancies: a retrospective study of 350 patients in a Finnish tertiary care hospital. Leuk Lymphoma. 2015;56:3370–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Trecarichi EM, Pagano L, Candoni A, Pastore D, Cattaneo C, Fanci R, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect. 2015;21:337–43.CrossRefPubMedGoogle Scholar
  7. 7.
    Tang Y, Cheng Q, Yang Q, Liu J, Zhang D, Cao W, et al. Prognostic factors and scoring model of hematological malignancies patients with bloodstream infections. Infection. 2018;46:513–21.CrossRefPubMedGoogle Scholar
  8. 8.
    Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care. 2014;18:596.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ramphal R. Importance of adequate initial antimicrobial therapy. Chemotherapy. 2005;51:171–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother. 2005;49:760–6.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European conference on infections in leukemia. Haematologica. 2013;98:1826–35.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrob Agents Chemother. 2014;58:3799–803.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Fu-pin HU, Guo Y, Zhu D, et al. CHINET China bacterial resistance surveillance in 2017. Chin J Infect Chemother. 2018;2018:241–251.13.Google Scholar
  14. 14.
    de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010;21:v252–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:794–810.CrossRefPubMedGoogle Scholar
  16. 16.
    Russell JA. Management of sepsis. N Engl J Med. 2006;355:1699–713.CrossRefGoogle Scholar
  17. 17.
    Hall KK, Lyman JA. Updated review of blood culture contamination. Clin Microbiol Rev. 2006;19:788–802.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ghafur A, Devarajan V, Raja T, Easow J, Raja MA, Sreenivas S, et al. Monotherapy versus combination therapy against carbapenem-resistant Gram-negative bacteria: a retrospective observational study. Indian J Cancer. 2016;53:592–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.CrossRefPubMedGoogle Scholar
  20. 20.
    Liu J, Cheng Q, Yang Q, Li X, Shen X, Zhang L, et al. Prognosis-related factors in intensive care unit (ICU) patients with hematological malignancies: a retrospective cohort analysis in a Chinese population. Hematology. 2015;20:494–503.CrossRefPubMedGoogle Scholar
  21. 21.
    Marin M, Gudiol C, Ardanuy C, Garcia-Vidal C, Jimenez L, Domingo-Domenech E, et al. Factors influencing mortality in neutropenic patients with haematologic malignancies or solid tumours with bloodstream infection. Clin Microbiol Infect. 2015;21:583–90.CrossRefPubMedGoogle Scholar
  22. 22.
    Agrawal GN, Shevade SU. Comparison of Clinical and Laboratory Standards Institute 2008 and 2010 guidelines in interpreting susceptibility of enterobacteriaceae isolates. Indian J Pathol Microbiol. 2014;57:518–9.CrossRefPubMedGoogle Scholar
  23. 23.
    De Rosa FG, Pagani N, Fossati L, Raviolo S, Cometto C, Cavallerio P, et al. The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria. Infection. 2011;39:555–61.CrossRefPubMedGoogle Scholar
  24. 24.
    Vasudevan A, Chuang L, Jialiang L, Mukhopadhyay A, Goh EY, Tambyah PA. Inappropriate empirical antimicrobial therapy for multidrug-resistant organisms in critically ill patients with pneumonia is not an independent risk factor for mortality: results of a prospective observational study of 758 patients. J Glob Antimicrob Resist. 2013;1:123–30.CrossRefPubMedGoogle Scholar
  25. 25.
    Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother. 2010;54:1742–8.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Su TY, Ye JJ, Hsu PC, Wu HF, Chia JH, Lee MH. Clinical characteristics and risk factors for mortality in cefepime-resistant Pseudomonas aeruginosa bacteremia. J Microbiol Immunol Infect. 2015;48:175–82.CrossRefPubMedGoogle Scholar
  27. 27.
    Erbay A, Idil A, Gozel MG, Mumcuoglu I, Balaban N. Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents. 2009;34:575–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Ozyilkan O, Yalcintas U, Baskan S. Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients. Korean J Intern Med. 1999;14:15–9.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Zhai W, Zhang X, Wei J, Deng Q, Dong X, Zhang X, et al. A prospective observational study of antibiotic therapy in febrile neutropenia patients with hematological malignances from multiple centers in Northeast China. Int J Infect Dis. 2015;37:97–103.CrossRefPubMedGoogle Scholar
  30. 30.
    Cendejas-Bueno E, Romero-Gomez MP, Mingorance J. The challenge of molecular diagnosis of bloodstream infections. World J Microbiol Biotechnol. 2019;35:65.CrossRefPubMedGoogle Scholar
  31. 31.
    Cha MK, Kang CI, Kim SH, et al. In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia. Antimicrob Agents Chemother. 2015;59:5834–7.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Hematology, The Third Xiangya HospitalCentral South UniversityChangshaChina
  2. 2.Department of Emergency, The Third Xiangya HospitalCentral South UniversityChangshaChina

Personalised recommendations